X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
0
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
Details:
MAT2203 (amphotericin B) is an orally administered lipid nanocrystal (LNC) formulation of amphotericin B, which is being evaluated for the treatment of invasive fusarium infection.
Lead Product(s): Amphotericin B
Therapeutic Area: Infections and Infectious Diseases Product Name: MAT2203
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 22, 2024
Details:
MAT2203 (amphotericin B) is an oral formulation based on the LNC platform delivery technology. It is being evaluated in preclinical studies for the treatment of invasive aspergillosis with limited or no treatment options.
Lead Product(s): Amphotericin B
Therapeutic Area: Infections and Infectious Diseases Product Name: MAT2203
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 26, 2024
Details:
MAT2203 (amphotericin B) acts by binding to the sterol component of a cell membrane leading to alterations in cell permeability & cell death. It is being evaluated for the treatment of invasive aspergillosis.
Lead Product(s): Amphotericin B
Therapeutic Area: Infections and Infectious Diseases Product Name: MAT2203
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 20, 2024
Details:
The partnership will allow Cipla to scale up the product, conduct the required studies, and seek regulatory approvals for the commercialization of amphotericin, which is being evaluated in the preclinical studies for the treatment of Fungal keratitis.
Lead Product(s): Amphotericin B
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Cipla
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership February 15, 2024
Details:
MAT2203 (amphotericin B) is an oral formulation based on the LNC platform delivery technology. It is being evaluated in preclinical studies for the treatment of invasive aspergillosis with limited or no treatment options.
Lead Product(s): Amphotericin B
Therapeutic Area: Infections and Infectious Diseases Product Name: MAT2203
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 21, 2023
Details:
MAT2203 is a potential oral formulation broad-spectrum treatment for invasive deadly fungal infections. Although amphotericin B is a fungicidal agent, it is currently only available through an intravenous, while MAT2203 has oral route of administration.
Lead Product(s): Amphotericin B
Therapeutic Area: Infections and Infectious Diseases Product Name: MAT2203
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 11, 2023
Details:
MAT2203 (amphotericin B) is an oral, LNC formulation of the highly effective, but also highly toxic, antifungal medicine amphotericin B, primarily used as a first-line treatment for invasive fungal infections.
Lead Product(s): Amphotericin B
Therapeutic Area: Infections and Infectious Diseases Product Name: MAT2203
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 21, 2022
Details:
Late-breaking data demonstrate that MAT2203 achieves impressive in vivo efficacy and has in vitro killing activity 5 to 10-fold higher than liposomal amphotericin B against two clinical isolates of pulmonary mucormycosis.
Lead Product(s): Amphotericin B
Therapeutic Area: Infections and Infectious Diseases Product Name: MAT2203
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: University of Minnesota
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 12, 2022
Details:
MAT2203, (amphotericin B) oral formulation utilizes the Company’s proprietary LNC technology to deliver amphotericin B in a way that targets infected tissues and avoids the toxicity normally seen with intravenously administered amphotericin B.
Lead Product(s): Amphotericin B
Therapeutic Area: Infections and Infectious Diseases Product Name: MAT2203
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 25, 2022
Details:
Abbreviated New Drug Application (ANDA) for generic Amphotericin B Liposome for Injection, 50 mg/vial Single-Dose Vial. The generic product approval is based on AmBisome® Liposome for Injection, 50 mg/vial as a reference product.
Lead Product(s): Amphotericin B
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 15, 2021
Details:
SP Accure Labs has launched alternative drug amphotericin-B-emulation, an Ergosterol sequestering agent, for the effective treatment of mucormycosis (black fungus). This new drug will be available in the market in a week at Rs. 5,400 per injection.
Lead Product(s): Amphotericin B
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 08, 2021
Details:
The Company is a specialist in the Liposomal technology and has once again stepped ahead to offer Liposomal Amphotericin B, the drug of choice for initial therapy of mucormycosis and a product which is the need of the hour to fight the menace of Black fungus.
Lead Product(s): Amphotericin B
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 20, 2021
Details:
The partnership aims to support the TLC for the launch and commercialization of their lead product AmphoTLC (amphotericin B) in India. It will be indicated for the COVID-19-associated mucormycosis cases.
Lead Product(s): Amphotericin B
Therapeutic Area: Infections and Infectious Diseases Product Name: AmphoTLC
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Strides Pharma Science
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership March 19, 2021
Details:
DSMB evaluated both safety and efficacy data in recommending cohort progression. EnACT is a Phase 2 prospective cohort study is evaluating the safety, tolerability and efficacy of MAT2203 in approximately 100 HIV-infected patients with cryptococcal meningitis.
Lead Product(s): Amphotericin B
Therapeutic Area: Infections and Infectious Diseases Product Name: MAT2203
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 19, 2020
Details:
The 2g dose will be tested in the 2-week induction phase of treatment. Data from Part 1 demonstrated that MAT2203 was safe and well tolerated across all three daily doses tested
Lead Product(s): Amphotericin B
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 19, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
